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Abstract
Background: Early Intervention in Psychosis (EIP) services improve health outcomes for young people with
psychosis in the medium–long term, but 25% of young people disengage in the first 12 months with costs to their
mental health, families, society and the NHS. This study will evaluate the effectiveness, cost-effectiveness and
implementation of a team-based motivational Early Youth Engagement (EYE-2) intervention.
Method: The study design is a cluster randomised controlled trial (RCT) with economic evaluation, comparing the
EYE-2 intervention + standardised EIP service to standardised EIP service alone, with randomisation at the team
level. A process evaluation will evaluate the delivery of the intervention qualitatively and quantitatively across
contexts.
The setting is 20 EIP teams in 5 sites: Manchester, South London, East Anglia, Thames Valley and Hampshire.
Participants are young people (14–35 years) with first episode psychosis, and EIP staff.
The intervention is the team-based motivational engagement (EYE-2) intervention, delivered alongside standardised
EIP services, and supported by additional training, website, booklets and social groups. The comparator is the
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standardised EIP service. Both interventions are delivered by EIP clinicians.
The primary outcome is time to disengagement (time in days from date of allocation to care coordinator to date of
last contact following refusal to engage with EIP service, or lack of response to EIP contact for a consecutive 3-
month period). Secondary outcomes include mental and physical health, deaths, social and occupational function,
recovery, satisfaction and service use at 6, 12, 18 and 24 months.
A 12-month within-trial economic evaluation will investigate cost-effectiveness from a societal perspective and from
an NHS perspective.
Discussion: The trial will provide the first test of an engagement intervention in standardised care, with the
potential for significant impact on the mental health and wellbeing of young people and their families, and
economic benefits for services. The intervention will be highly scalable, supported by the toolkit including manuals,
commissioning guide, training and resources, adapted to meet the needs of the diverse EIP population, and based
on an in-depth process evaluation.
Trial registration: ISRCTN 51629746 prospectively registered 7th May 2019. Date assigned 10th May 2019.
Keywords: Psychosis, Early intervention, Engagement, Intervention, RCT, Economic evaluation, Process evaluation
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Introduction
Background and rationale {6a}
In England, 1–2% of the population [1] or 7500 new
young people each year [2] develop psychosis. Psychosis
can have devastating consequences, with significantly
poorer quality of life and high disability adjusted life
year losses [3]. People with psychosis die up to 25 years
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earlier than the general population [4], one third from
suicide, usually within the first 3–5 years from diagnosis
[5, 6]. The first 2–3 years are pivotal in determining long-
term trajectories [7–12]. Early Intervention in Psychosis
(EIP) services are pro-active, person-centred mental health
services offering early detection and treatment in this crit-
ical 3-year period [2, 13–24]. The recent Access and Wait-
ing Time Standards [25], published in 2016 by NHS
England, require that Clinical Commissioning Groups
offer a National Institute for Health and Care Excellence
(NICE) concordant EIP service within 2 weeks from refer-
ral for all new emerging psychosis cases in England.
Despite these guidelines, treatment disengagement from
services is high [26–33]: estimated at 30% of young people
in a recent systematic review across all service types and
follow-up periods [26], and 25% within the first 12months
in standalone EIP services [27, 28], including in our own
pilot study [34–36]. This is a significant problem. National
policy, investment and service structure are focused on
ensuring that young people are proactively engaged in as-
sessment and offered a full EIP care package to prevent
them ‘falling through the gaps’, receiving inadequate care,
poor outcomes and greater subsequent healthcare use
[25], but 1 in 4 disengage. There is limited evidence for
methods to promote engagement in the subsequent
3 years. Our work has begun to provide this evidence [34–
37]. We now understand why people disengage and are
testing the effectiveness and cost-effectiveness of a team-
based motivational engagement intervention to reduce
disengagement from EIP services.
There is sustained interest in increasing access to EIP
services for people of all ages who develop a first
episode of psychosis, and a clear need to prevent
disengagement. Engagement with EIP services leads to
increased service user satisfaction, fewer symptoms,
relapses and hospital admissions, better health,
wellbeing, social and occupational function and fewer
suicides [12, 38–41] in the medium to long term [17–20,
38]. Disengagement of young people with psychosis
represents a significant cost to their health and
wellbeing and impacts on families, society and the NHS.
There is an expressed need from researchers and NHS
management to focus on engagement, with some
researchers suggesting it is the most important outcome
of EIP services [42]. The College Centre for Quality
Improvement has made time to disengagement a recent
EIP audit requirement [43]. Furthermore, Access and
Waiting Time Standards are supported by NHS England,
who are committed to further access and engagement
targets up to 2020 [25]. EIP service access is ‘a clear
national priority for the NHS’, and local NHS services
must include EIP development in their immediate and
long-term sustainability and transformation plans [25].
This commitment has been supported by £70 million for
staff and training to 2020 [44]. Yet disengagement from
these services threatens the quality of health outcomes
and nullifies this investment for 25% of young people.
The financial cost of psychosis to society, including
healthcare, families, unemployment and death, is
estimated at £11.8 billion per year [45]. EIP services
demonstrate savings of 30–50% over standard care, over
periods of at least 8 years [46, 47]; £5000 per person per
year based on days in hospital [37]; £7972 net savings
per person after 4 years, £6870 in the next 4–10 years
and £15 for every £1 spent on EIP services after 10 years
[48]. Even with suboptimal engagement, EIP is estimated
to result in £63 million of savings per year to society,
£34 million of these to the NHS [49].
Our initial Early Youth Engagement (EYE) project [34–
36] developed a team-based motivational engagement
intervention, drawing on views of service users and their
families of barriers and facilitators to engagement, and on
literature that disengagement is linked to younger age,
substance use, coping styles, family contact and know-
ledge of services [26, 29, 31]. To date, limited evidence
from our own work identifies strategies to maintain en-
gagement from initial assessment or when a young person
begins to disengage. Our Delphi consultation with clini-
cians and managers reached consensus on the EYE inter-
vention and resources that were both important and
feasible to deliver, based on the views of young people and
their families. Our pilot study found that service disen-
gagement decreased from 24% prior- to 14.5% post-EYE
intervention. Qualitative data from service users, families
and staff revealed improvements in personal recovery (so-
cial inclusion, hope, trust, practical goals) and engagement
(communication, collaboration, family involvement). Fam-
ilies reported feeling more reassured that they knew how
to support their young person, and staff felt more pride
and professionalism in their service due to having access
to high-quality resources and information.
However, the original EYE pilot study was conducted on
only 298 service users, and whilst it showed promising
results in reducing disengagement, the pre- and post-
intervention comparison methodology was not designed
to formally assess the effectiveness of the intervention.
There was no evaluation of the cost-effectiveness of the
intervention and limited evaluation of implementation.
The current protocol presents the methodology of a
pragmatic cluster randomised controlled trial (RCT) to
investigate the effectiveness, cost-effectiveness and im-
plementation of the team-based motivational engage-
ment intervention aimed at reducing disengagement
from EIP services—the EYE-2 project.
Objectives {7}
Aims
The main research aims are:
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(i) To evaluate the effectiveness of the team-based mo-
tivational engagement EYE-2 intervention with re-
spect to the primary outcome, time to
disengagement and secondary outcomes: mental
and physical health, deaths (including suicide), so-
cial and occupational function, recovery, satisfaction
and service use derived from routine service data
(Health of the Nation outcome Scale (HoNOS),
Process of Recovery Questionnaire (QPR), DIALOG
questionnaire [50–52] at 0, 6, 12, 18 and 24months.
(ii) To determine societal and NHS costs, cumulative
cost savings and overall cost-effectiveness of im-
proved EIP engagement and produce a commission-
ing guide, with GP commissioner input.
(iii)To develop and test a framework for
implementation through a large-scale process evalu-
ation using (i) Normalisation Process theory (NPT)
[53] and (ii) logic models [54], incorporating all cli-
nicians involved in EYE-2 intervention delivery,
assessed through questionnaires and qualitative in-
terviews at the start, middle and end of the trial.
Hypotheses
The primary hypothesis is that, compared to standard
EIP alone, the EYE-2 intervention will increase time to
disengagement;
The secondary hypotheses are that, compared to
Standard EIP alone, the EYE-2 intervention will:
(i) Improve mental and health outcomes;
(ii) Improve recovery, social and occupational function,
and satisfaction;
(iii)Be cost-effective with potential societal and NHS
cost-savings.
(iv) Be moderated by effective implementation as
measured by the process evaluation questionnaires
Trial design {8}
Figure 1 comprises the SPIRIT (Standard Protocol
Items: Recommendations for Interventional Trials)
figure [55].
The trial is a parallel-group cluster RCT, with 1:1 allo-
cation by cluster, stratified by site, to test the effective-
ness and cost-effectiveness of the EYE-2 intervention in
reducing disengagement compared to standardised stan-
dalone EIP service.
Our success (go) criteria are
1. End of month 9—20 teams randomised
2. End of month 16—50% of participants identified
3. End of month 16—Initial fidelity data available at all
sites
Our stop criteria at which point the trial will be
considered infeasible will be if any of the following
apply:
1. End of month 12—< 17 (80% of teams) teams
randomised
2. End of month 19—< 40% of participants identified
3. End of month 19—Initial fidelity data available for
fewer than 3 sites
The cost-effectiveness study will comprise a 12-month
economic evaluation of the EYE-2 intervention under-
taken primarily from a societal perspective, accounting
for cost impacts within and beyond the mental health
sector, with a secondary cost-effectiveness analysis tak-
ing a narrower NHS perspective, focusing principally on
NHS mental health service utilisation. The economic
evaluation will include consideration of mental health
outcomes (measured through HoNOS) and improved
levels of engagement with EIP services. An alternative
24-month point will be considered however, if the in-
formed consent process leads to withdrawals.
A prospective mixed methods process evaluation will
investigate the delivery of the intervention. The process
evaluation will be longitudinal (over 2 years) and will be
informed by Normalisation Process Theory [53, 56–58]
and trial-specific logic models [54].
Methods: participants, interventions and
outcomes
Study setting {9}
The setting will be 20 UK EIP community teams in
South London; Manchester; Hampshire; Thames Valley
and East Anglia, derived from 9 NHS trusts across
England. Specific trust information is listed in the ISRC
TN trial registration.
Eligibility criteria {10}
All services meet the following specific inclusion criteria:
(i) standalone EIP site with at least 2 discrete services;
(ii) willingness and capacity for involvement as agreed
by clinical services; (iii) identified site principal
investigator with academic track record in leading RCTs
in psychosis; (iv) regional EIP support; (v) individual
service size of at least 35–40 new clearly defined first
episode cases per year aged 14–35; (vi) currently
capturing NHS England mandated routine outcome
data; (vii) systems (IT and staff) in place to increase
routine outcome data capture; (viii) geographical spread
to include urban and rural locations, ethnic minority
variations, and North and South of England.
Service user inclusion criteria are as follows: (i)
consecutive referrals to the EIP team during the study
recruitment period (ii) aged 14–35; (iii) meeting criteria
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for a first episode of psychosis (FEP): (F20-F29; F31
ICD-10) [59] as determined by each local service accord-
ing to their own established criteria. The inclusion cri-
teria used to make these decisions will be recorded for
each service and reported for subsequent inspection. Ex-
clusion criteria are (i) a sub-threshold ‘at risk mental
state’, not meeting FEP criteria, (ii) referral over the age
of 35, (iii) referrals where there is remaining diagnostic
uncertainty about psychosis at 12 months and (iv) ser-
vice exclusion criteria such as organic or intoxication in-
duced psychosis and specific exclusions.
Clinician inclusion criteria for the process evaluation
are all clinicians delivering EYE-2 and/or EIP services as
part of the RCT. Exclusion criteria are EIP clinicians
who are in the EYE-2 group but did not receive training
in the intervention and EIP clinicians across both groups
who did not provide consent.
Who will take informed consent? {26a}
This study presents unique challenges as the primary
‘disengagement’ outcome has the potential to impact
disproportionately on data completeness in those who
are disengaging, who are the least likely to consent. A
standard approach of receiving individual informed
consent and providing commensurate reimbursement
for time is likely to impact on robust data completion.
Fig. 1 SPIRIT figure. aRoutinely recorded by service and collated by RAs in teams. bRoutinely collected by clinicians and collated by RAs in teams.
cCollected by RAs for AD-SUS, people who disengage, and missing data
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As a result, this intervention will be primarily evaluated
using routinely available and routinely collected service
data. Data will be collated by the EIP Research Assistant
(RA) who will work as part of the clinical team and will
transfer anonymised service data to the research team.
The study will be widely publicised within each team to
all those who are eligible and defined as part of the
research cohort. They will receive a study information
leaflet, contact details for the trial, promotional material
and a pack of local support service information, as
recommended by our Patient and Public Involvement
(PPI) group. Any service user who requests that their
data are not used will be withdrawn from the trial. All
remaining service user data will be included.
Service users will be contacted directly for the purpose
of collecting a small amount of additional questionnaire
data, as part of a research process in which informed
consent will be taken, either (i) if a service user has
disengaged completely and routine service data are not
available or (ii) at the 12-month assessment when non-
routine health economic data are collected. In these
cases, a member of the clinical team or the clinical RA
will make the first contact. All service users who are
willing will then be contacted by the study RA who will
take informed consent for completion of questionnaire
data and will provide £20 remuneration for their time.
For the process evaluation, all EIP clinicians will be
invited to take part by the clinical RA. They will be
provided with an information and consent sheet in
advance and will provide written informed consent prior
to the process evaluation.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Not applicable. This trial does not involve collecting
biological specimens for storage. There are no ancillary
studies that require additional consent provisions.
Interventions
Explanation for the choice of comparators {6b}
The current EIP care pathway is variable nationally in
adherence to the EIP model, with standalone, hub and
spoke services, and specialist workers in community
teams. Standalone services that adhere to the EIP model
have the best outcomes [60, 61], and recent investment
and targets [25] mean many services are moving to this
model. All services involved in the current study are
standardised in that they are standalone services,
adherent to the EIP model core principles of (i) early
detection, (ii) assertive engagement, (iii) person and
recovery focus, (iv) family focus, (v) work with
diagnostic uncertainty, (vi) positive risk-taking and (vii)
provision of NICE-recommended interventions [22, 61].
We have selected the standardised EIP pathway as
the comparison condition because it is the nationally
recommended care pathway for people in England
who develop a first episode of severe mental illness
(psychosis). Delivery of this pathway and routine
outcome measures (HoNOS; QPR; DIALOG) [50–
52] are mandated by NHS England [25]. The EIP
service model and suite of NICE-recommended in-
terventions are clearly defined. Training and moni-
toring will ensure that administration and recording
of measures and intervention provision is under-
taken in the EIP pathway in a robust, standardised
way across sites.
Intervention description {11a}
Whilst the EIP model outlines what should be done, the
EYE-2 intervention is complementary to this pathway,
providing detail regarding how staff and teams should
operate, and the tools, resources and breadth of social
network with which they should work to promote better
engagement.
The team-based motivational engagement (EYE-2)
intervention is delivered by EIP clinicians during their
normal routine contacts throughout the entirety of the
trial period, supported by training, an intervention man-
ual, booklet series (Fig. 2), website (Fig. 3), friends and
family involvement and social groups protocol. It is in-
corporated into standard EIP teams.
The implementation tool kit is a set of resources
provided to each clinician as part of the training. It
comprises (i) the implementation manual; (ii) the
booklets (mental health and help-seeking, EIP, for
friends and family, treatment choices, (iii) the EYE-2
team and individual implementation checklists and (iv)
the links to the website and training videos.
The EYE-2 intervention is framed around a novel
therapeutic engagement model derived from a previous
study (The EYE project) [34–36] and a subsequent im-
plementation study. It is based on motivational inter-
viewing and open social communication and includes
the following approaches and resources to support
young people to reach their life and treatment goals:
1. Communication: transparent, open and honest
communication
All staff are trained by the EYE-2 team in open motiv-
ational communication approaches, supported by the
website and myth-busting booklet series, which address
young people’s real concerns in a direct, honest manner.
2. Social involvement: support of the whole social
network
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Staff and service users are encouraged to draw on a
wide social network of friends, family and peers, in
pursuit of the young person’s goals, supported by the
friends and family booklet and service user-led social
groups run by the PPI lead, and RA, that focus on young
people’s own goals and interests and encourage young
people to support each other. Training is provided in
carers’ rights, and in processes for involving friends and
family.
3. Mental health service: collaboration and choice
regarding difficult treatment issues
Collaboration and choice are supported by the staff
training, and service user-led training videos, shown dur-
ing the staff training, and available on the EYE-2 website
regarding difficult treatment issues, risk and hospital
admission, which ordinarily impact on engagement. It is
supported by the ‘challenges you may face’ section on
treatment in the Family and Friends booklet and by the
‘Treatment choices booklet’, a comprehensive, highly
valued, user-friendly, honest review of treatment options,
co-produced with service users, carers, and all clinical
disciplines.
4. Mental health staff: hopeful support for meaningful
goals and needs
The staff training, based on motivational interviewing
and open social communication, is supported by service
user-led training videos and promotes a hopeful, motiv-
ational, goals-focussed approach. Website resources will
enable staff to be knowledgeable, with information at
their fingertips to support their service users.
Fig. 2 EYE-2 intervention booklets for service users
Fig. 3 Homepage of the EYE-2 website for service users
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5. Addressing personal barriers
Personal barriers to engagement are addressed by
reaching out to service users through the discussion
forum on the website, the ‘addressing personal barriers
to talking’ sections in the booklets, and the social groups
that are attended and co-led by service users.
Criteria for discontinuing or modifying allocated
interventions {11b}
Consistent with the engagement approach, a service user
and clinician work together such that the intervention
delivery is tailored to the needs and preferences of the
service user. Any concerns over safety will be identified
through adverse reactions (ARs) and serious adverse
reactions (SARs), and modification to the overall
intervention will in the first instance occur through
protocol amendments.
Strategies to improve adherence to interventions {11c}
Adherence to the intervention will be supported by the
implementation toolkit (manual, resources and EYE-2
checklist), initial and booster training programme, and
large-scale process evaluation, and by additional re-
sources and activities that are requested to support im-
plementation throughout the trial.
EYE-2 training programme The EYE-2 training is de-
livered by the chief investigator and research fellow, sup-
ported by the site PPI team (PPI lead, 1–2 local service
users, and 1 local carer who will provide a local perspec-
tive on service provision and the EYE-2 approach), and
practically by the EIP RA. The training will last 1.5 days.
Core sessions include (i) introduction to the EYE-2
intervention and resources, (ii) the value of hopeful care
coordination, (iii) goal-focussed care planning, (iv) ser-
vice user-led introduction to honest open communica-
tion, (v) carers rights and protocol for engaging family
and friends, (vi) peer workers and social groups, (vii)
motivational interviewing for goal-focussed engagement,
(viii) applying open communication approaches in the
context of risk, mental health exacerbations, treatment
and admissions, (ix) the implementation process and
local implementation plans and (x) the research
process—ethics, consent, promotion and awareness rais-
ing. Two rounds of each training are offered at each site,
at least 1 month apart, to enable staff to attend whilst
maintaining service delivery, and to accommodate leave
and absence. A preparation and consolidation phase of
up to 1 month will allow final preparations for RCT
start. Additional booster training will be offered approxi-
mately 6-monthly throughout the intervention, with
content being informed by feedback collected in earlier
training, in the qualitative interviews, and from staff at
study sites.
Adherence monitoring in the process evaluation
Monitoring of adherence to the intervention will be
informed by the process evaluation questionnaire data
which will be collected from all consenting clinicians at
3 time points (start, middle, end) during intervention
delivery, and from the team clinical RA in each team.
The questionnaires will evaluate adherence to the EIP
and EYE-2 intervention models, individual and team pol-
icies and practices. The EYE-2 questionnaires will be
used to describe a threshold for effective implementation
based on clinicians’ use of EYE-2 resources with EYE-2
service users. A random sub-sample of 33–40 clinicians
across all EYE-2 teams at the same three time points will
complete a brief semi-structured interview to explore
barriers and facilitators to intervention delivery in more
detail in relation to context and turbulence. Baseline and
mid-trial fidelity assessments will be summarised and
fed back to services to boost fidelity.
Contamination protocol A contamination protocol will
be provided to teams to ensure that resources are not
shared outside of EYE-2 teams, that staff who move
from an EYE-2 team to a standard EIP team do not take
resources with them, and wherever possible, that they do
not work directly with the study cohort participants
from the control group. We will monitor any transfer of
EYE-2 resources between study groups, and any relevant
training.
Relevant concomitant care permitted or prohibited during
the trial {11d}
There will be no restrictions to the usual concomitant
care and interventions provided during the course of the
trial. A case note screen will record NICE guidelines
interventions provision.
Provisions for post-trial care {30}
Ancillary and post-trial care will be provided by standard
NHS EIP services, except for service users who have vol-
untarily disengaged from services, who will be provided
with information on local support services, and appro-
priate NHS services as required during any research
assessment.
Outcomes {12}
Outcomes will be reported separately for the RCT,
health economic evaluation and process evaluation.
RCT outcome measurement
The primary outcome for the RCT is time to
disengagement [28]. Secondary outcomes will comprise
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the NHS England mandated routinely collected
clinician-rated [50] and patient-reported outcomes [51,
52] at 0, 6 and 12months (18 and 24 for those identified
in the 0–6 months of the trial). These secondary out-
comes evaluate behavioural, functional, mental and
physical health and social-occupational problems,
patient-reported recovery, subjective quality of life and
treatment satisfaction. Service use in terms of provision
of NICE-recommended interventions, and deaths will
also be documented.
Health economic evaluation
The primary outcome will be the Adult Service Use
Schedule (AD-SUS) [62, 63], administered at 12 months,
which will measure, through participant self-report,
wider service use over follow-up and employment-
related outcomes. To support the economic evaluation,
a common NHS England mandated dataset will be used
to measure patient outcomes (HoNOS scores) and re-
source use pertaining to contact with EIP and other in-
terventions developed for this patient group, psychiatric
inpatient admissions, service use relating to section 136
and A&E contacts will also be recorded.
Process evaluation outcome
Implementation of the intervention will be evaluated
longitudinally at 3 time points (early, middle and end of
the trial) using both questionnaires (EYE-2 and EIP
checklists, and the NOMAD tool, [64] which explores
attitudes and behaviours towards implementation-based
on normalisation process theory) and qualitative
interviews.
Participant timeline {13}
Figure 1 illustrates the SPIRIT figure for EYE-2.
Sample size {14}
Time to disengagement will be analysed using frailty
analysis to adjust for clustering by service. Simulation
confirms that 10 clusters per group (n = 950) will
achieve 90% power to detect a difference corresponding
to 12-month disengagement rates of 25% (standard 12-
month disengagement rate from EIP service) [26–28] vs
15%, assuming time to disengagement has an exponen-
tial distribution; intracluster correlation of 0.05 [65]
drop-out rate of 10% per year; conservative significance
level of 3% to correct for inflation of type I error due to
small cluster numbers; variable cluster size modelled as
a uniform random variable between 35 and 60; recruit-
ment at referral; and 12 months recruitment plus 12
months follow-up. Simulations were conducted using




The EIP RA working as part of the EIP clinical team in
each service will work with the lead clinicians in the
clinical team and with reference to the eligibility criteria
to determine the cohort of eligible service users in that
service. All consecutively referred service users during
the recruitment period, who meet criteria, and do not
ask to be withdrawn, will form the cohort in each team.
Unclear cases will be discussed and agreement reached
with the site principal investigator (PI) and study chief
investigator (CI).
For the training and process evaluation questionnaire
study, all clinicians will be invited to take part verbally
and via an online link in an email. A threshold will be
set for sufficient staff consent to warrant service entry
into the trial. This threshold will be set to at least 80%
of all care coordinators, and the team leader, consenting
to take part to further ensure that sufficient staff
received training to deliver the intervention. For the
qualitative study, 33–40 clinicians will be randomly
selected from among those who provide consent,
sampled purposively to include all clinicians and
managers across all 10 EIP teams, to take part in an
individual interview.
Assignment of interventions: allocation
Sequence generation {16a}
The statistician at the Brighton and Sussex Clinical
Trials Unit (CTU) generated a randomisation list
comprising permuted blocks of size 2, stratified by site
(Manchester, London, Thames Valley, East Anglia,
Hampshire) using a tool provided by Sealed Envelope™
[68], an independent online randomisation service.
Concealment mechanism {16b}
To achieve statistician blinding and to ensure
concealment, this was sent to an independent statistician
(AMJ) to combine with the teams list, itself randomly
ordered within site, by sorting a random number list,
which she uploaded to Sealed Envelope.
Implementation {16c}
The research fellow requested the password-protected
concealed allocations online once all the participating
teams at a site had reached the threshold for care coord-
inator and staff recruitment (≥ 80%) and were ready to
start.
Assignment of interventions: blinding
Who will be blinded {17a}
All researchers involved in the analysis of trial
effectiveness and cost-effectiveness data will be blind to
allocation status. This includes members of the Brighton
and Sussex CTU, statisticians carrying out the RCT
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analyses, and health economists conducting the cost-
effectiveness analysis. In addition, each site will be
allocated a ‘blinded’ RA who will code the primary ‘time
to disengagement’ trial outcome measure and collect the
primary AD-SUS cost-effectiveness data blind to study
group. They will also collect additional 12-month data,
and data from participants who disengage, blind to study
group. Blinding will be ensured by situating blinded re-
searchers in a separate site or building from remaining
trial team members, and by ensuring separate sections of
meetings, and separate documents as necessary for
blinded and unblinded researchers. We will record when
data have been collected blind and unblinded for subse-
quent inspection. A full statistical analysis plan will be
written and independently reviewed prior to final ana-
lysis being undertaken by the trial statistician who will
be kept blind to which trial group is which. Service
users, clinicians, remaining local site teams (EIP RA, PPI
lead, principal investigator/site lead), trial manager and
chief investigator will not be blind to study allocation.
Procedure for unblinding if needed {17b}
As noted above, service users, clinicians and local site
teams will already be unblinded, so this is not applicable.
Data collection and management
Plans for assessment and collection of outcomes {18a}




There are 3 main methods of data collection in this
study that have been specifically designed to maximise
data completeness (see Fig. 1). First, primary outcome
data are recorded routinely by the service, but collated
by the RA working within the EIP service and
transferred anonymously to the research team
(disengagement and service use data, as well as data on
use of NICE interventions). The primary outcome of
time to disengagement will be calculated by the blinded
RA who will determine date of disengagement (date of
last contact with the team) and calculate the number of
days from allocation to care coordinator to
disengagement using casenote data provided by the EIP
RA, who will double check the data using the same
process, and any discrepancies will be resolved in
discussion with the study team. Second, there are data
that are routinely collected by EIP clinicians but collated
by the researchers (HoNOS; QPR; DIALOG) and
transferred anonymously to the study team. These
researchers in their role with the team will also collect
additional missing routine data. Finally, where routine
data are missing at 12 months, for cost-effectiveness data
(AD-SUS), and for routine data from those who disen-
gage, a standard informed consent process will be taken
prior to data collection as described above, and data in-
cluding HoNOS, QPR and DIALOG will be collected by
telephone or in person. If the service user prefers to
complete the questionnaires by telephone, consent will
be noted by the researcher, after which the researcher
will conduct the HoNOS using a semi-structured inter-
view developed for this purpose in collaboration with
the Patient and Public Involvement team, as well as the
QPR, the DIALOG and the AD-SUS at 12 months. If
service users prefer to complete the data in person, then
written informed consent will be taken, a convenient
public space will be agreed to meet to complete the
measures, and the same process will be followed. Partici-
pants will be reimbursed £20 for their time in cash, or as
an Amazon.com voucher. If at any point the participant
asks to stop taking part, this will be noted and the inter-
view will be stopped. If the participant asks not to be
contacted again regarding the study, this too will be
noted, and they will not be contacted again. We will rec-
ord the nature of data collection (clinician, telephone as-
sessment or case note screen) for all outcomes.
Engagement and service use data will be captured
continuously from case notes. Secondary routine
clinician-rated (HoNOS) and patient-reported (QPR/DI-
ALOG) questionnaire data will be collected at 0, 6, 12,
18 and 24 months. Baseline will comprise the first − 4 to
+ 6 weeks to allow for baseline assessments in hospital
immediately prior to EIP allocation; follow-up data will
be collected at each time point − 2/+ 4 weeks. The study
will include a 12-month recruitment period and an add-
itional maximum 12-month follow-up period. Those
who enter the study at the start of the cohort will be
followed up for 24 months, whilst those who enter at the
end of the cohort will be followed up for 12 months.
Clinician training in robust data collection
An initial half-day training will be provided for clinicians
in both EYE-2 and control teams at each site on robust
data collection and recording. This will be supported by
a data collection manual and coloured user-friendly
questionnaire packs and resources. The training will in-
clude (i) team values and data collection, (ii) an intro-
duction to the questionnaires, (iii) identifying and
overcoming barriers to data collection, (iv) clinically
meaningful use in care planning (v) top tips and re-
sources to support implementation. This training
programme has been adopted by NHS England and
translated into an e-learning package for all EIP services
h t t p s : / /www . e - l f h . o r g . uk /p rog r ammes / e a r l y -
intervention-in-psychosis/. It is incorporated into
current National Clinical Audit of Psychosis outcomes
training. The full training package will thus be 1/2 a day
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on robust data collection training for control sites and a
2-day training to include also the EYE-2 training at
intervention sites.
Researcher training in data collection and data entry
RAs will be provided with initial training in cultural
differences by author SR, based on her cultural
adaptation framework with additional information
gained from earlier EYE-2 work. The model uses the
bio-psycho-spiritual-social model of illness, taking into
account the philosophical orientation of the individ-
ual, societal factors that impact on experiences, trust
and technical adjustments to interventions, including
the role of religion and spirituality and concepts such
as body and mind, self and other, individual and
collective goals [69–72].
Researchers will also be trained in study procedures,
data collection and intervention support roles,
MACRO data entry procedures and protocols. They
will be supervised by the site PIs and research trial
manager. Checks will be undertaken of the accuracy
of data coding and entry at each site, by the blind
RA.
Process evaluation questionnaire data will be
collected from all consenting clinicians at 3 time
points (start, middle, end) during intervention
delivery. The questionnaires will take 20–30 min and
can be completed online by email link, or by
telephone, or in person, at an NHS base or elsewhere
local to the clinician. All clinicians and managers in
each intervention team will be invited to complete
the process evaluation questionnaires. A random sub-
sample of at least 2 clinicians and 1 manager at each
of the 10 intervention services (n = 33–40) will also
complete a brief semi-structured interview to explore
barriers and facilitators to intervention delivery in-
cluding context and turbulence at 3 time points, with
at least 10 participants completing each time point of
beginning, middle and end of the intervention. Each
clinician will be interviewed in a face-to-face or tele-
phone individual interview with a clinical EIP re-
searcher from another site, at a time and place that is
convenient to them. The interview will take 20–30
mins and will be audio-taped for subsequent tran-
scription. It will be guided by the process evaluation
topic guide. The process evaluation topic guide will
be informed by Normalisation Process Theory and
the logic model for EYE-2.
Description of outcomes and their reliability and validity
Primary RCT outcome The primary outcome is time to
disengagement (in days, from date of allocation to care
coordinator to date of last contact following either
refusal to engage with an EIP team or lack of response
to EIP contact for 3 consecutive months). For
participants who remain engaged until the end of the
study follow-up period, time to disengagement is treated
as censored (unknown) beyond this point. This defin-
ition is widely used in engagement research [28, 31, 73,
74]. People who engage intermittently every few weeks
or via text or phone would still be engaged. Service users
who move to a service not in the study, or to the oppos-
ite study group, or move out of the UK and cannot be
referred to a mental health service will no longer be re-
ceiving the intervention are deemed lost to follow-up.
Secondary RCT outcomes
1. Health of the Nation Outcome Scale (HoNOS [50];)
The HoNOS is a 12-item clinician-rated scale, which
covers key health and social outcomes under four sub-
scales of behavioural (aggression, self-harm, substance
use), functional (cognitive and physical), mental health
(psychosis, depression, other) and social-occupational
problems (relationships, activities of daily living, living
conditions and occupation). Each item is rated from 0 (no
problem) to 4 (very severe), for the preceding 2 weeks and
summed to produce a total and subscale scores. The
HoNOS is used to ‘cluster’ mental health service users ac-
cording to clinical need. These clusters map onto NHS
commissioning tariffs and can be used to determine cost-
savings. It has good internal consistency and validity and
adequate sensitivity to change [75, 76].
2. Process of Recovery Questionnaire (QPR [51];)
The Process of Recovery Questionnaire is a 15-item
patient-reported outcome measure, developed by psych-
osis service users to capture recovery. Items include so-
cial inclusion, assertiveness, motivation, positive
relationships, purpose, empowerment, self-esteem, self-
efficacy, meaningful activity, understanding, acceptance,
enjoyment and positive risk-taking, each rated on a 5-
point scale from strongly disagree to strongly agree. In-
ternal consistency is 0.89, convergent validity is 0.73,
test–retest reliability is 0.74 and sensitivity to change is
0.40 [77].
3. DIALOG [52]
The DIALOG assesses patient-reported satisfaction
across two subscales of (i) subjective quality of life in-
cluding health (mental and physical), function (work,
leisure), social (friendships/family relationships), accom-
modation and personal safety; and (ii) treatment satisfac-
tion (practical and mental health support, medication)
all rated on a 7-point scale from Totally Dissatisfied to
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Totally Satisfied. It has adequate reliability (Cronbach’s
alpha = .57–71) and is valid (r = 0.95 with Manchester
Assessment of Quality of Life) [52].
4. NICE-recommended intervention use
Use of NICE-recommended interventions is recorded
on electronic care record systems as SNOMED-CT (Sys-
tematized Nomenclature of Medicine Clinical Terms)
Terms, a set of comprehensive scientifically validated
terms used internationally, and designated for NHS use
[26]. Relevant codes for EIP are Cognitive Behaviour
Therapy for psychosis, Family Interventions for Psych-
osis, Antipsychotic medication and monitoring, Physical
Health interventions and monitoring, Supported em-
ployment and vocational/educational rehabilitation; care
and treatment planning, substance use assessment and
intervention.
Cost-effectiveness outcomes The primary outcome will
be societal service use. NHS service use will be the
secondary outcome. The primary endpoint will be at 12
months.
1. Adult service use schedule [62, 63]
The AD-SUS is a structured questionnaire designed to
elicit self-reported contact with services and employ-
ment outcomes across a wider spectrum of services in-
cluding primary care, social services, police and criminal
justice contacts, education and training services and oc-
cupational outcomes. It has been used widely in various
forms in economic evaluations of child/adolescent and
adult mental health services.
2. Service use and deaths
Service use data, as advised by our GP commissioner,
will include (i) number of days spent in hospital; (ii)
number of A&E presentations and (iii) number of
instances of section 136 use. Deaths including from
suicide will also be recorded.
Process evaluation outcomes Primary outcome will be
delivery across sites as measured in the EYE-2 group by
(1) the EYE-2 checklist, which assesses individual and
team adherence to the EIP and EYE-2 model, access to
relevant training (motivational interviewing, open dia-
logue, EIP or engagement), the working alliance inven-
tory and subscales of the spontaneous self-affirmation
measure. (2) The NOMAD tool [64] which will explore
attitudes and behaviour towards the intervention in-
formed by Normalisation Process Theory and logic
models; and in the control group by (1) an adapted EIP
checklist, similar to the one above to assess adherence to
the EIP model, working alliance, self-affirmation, rele-
vant training, principles of good practice that are pro-
moted in the EYE-2 model, and inadvertent access to
EYE-2 intervention resources.
Elements of the Royal College of Psychiatrist EIP self-
assessment tool [43] and other national and local
service-level data will be collected in both groups to de-
scribe service delivery and context.
EIP RAs will also complete a second section of the
EYE-2–EIP checklist that relates to broad service profiles
and practices that are proposed to influence EYE-2 and
EIP delivery. The questionnaire will be completed with
reference to team policies and in consultation with the
team leader and will be conducted in all teams in both
groups of the study.
Secondary outcomes will be the thematic framework
derived from the qualitative sub-study that influences
delivery, including context and turbulence.
Plans to promote participant retention and complete
follow-up {18b}
Research suggests that follow-up rates are improved by
using shorter assessments, reminding service users about
subsequent follow-up, updating contact details, provid-
ing reimbursement, and utilising RAs to collect add-
itional data [78, 79]. We have incorporated all of these
approaches into the current strategy. Patient-reported
outcomes are brief (approximately 15 min, 25 min in-
cluding the Adult Service Use Schedule) and can be
completed by telephone. Participants will be advised that
they may be contacted and will be reimbursed £20 for
their participation. The maximum follow-up rate of 8
questionnaire assessments per RA per week if no data
are available routinely is achievable based on previous
research in these sites. The use of routine outcome data
will reduce the risk of disproportionate data loss for par-
ticipants who are minimally engaged.
RAs have a range of approaches to enhance
completion of secondary routine data collection. The
clinical EIP RA will provide reminders to clinicians
when routine outcomes are due and overdue. They will
provide individual outcome graphs for service users,
clinicians and whole team graphs, once follow-up out-
comes are available, to promote clinically meaningful
use. The research team will provide a monthly report of
data completeness and missing data, by team and site, to
site PIs, team lead and clinical link person in each team.
This will raise awareness regarding follow-up rates and
missing data. The clinical EIP RA can also collect miss-
ing routine data in person or by telephone on behalf of
the team. Participants who disengage will be invited to
provide data as part of a research process.
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Data management {19}
Data quality
The CTU data manager and trial manager will
undertake data quality checks in accordance with the
data management plan, supported by close liaison with
the site PIs and RAs at each site. The CTU will develop
an electronic Case Report Form (eCRF), using Elsevier
MACRO™. The system is Good Clinical Practice (GCP)
and 21 CFR Part 11 compliant with a full audit trail and
database lock functionality. Staff at each site will be
trained to ensure that data are captured reliably using a
standard eCRF proforma according to the processes
defined above. Proforma data will be recorded
anonymously using a distinct code to represent each
service user, monitored for completeness, collated and
entered consistently in anonymised form by the clinical
EIP RA in each service on the MACRO database for the
CTU and analysis team who will be blind to study
group. Limits will be placed on variable ranges in the
eCRF to reduce risk of inaccurate data entry. The RA
who will also be blind to study group will enter data that
is collected following informed consent. The CTU will
monitor for data completeness and accuracy on a
monthly basis. The statistician will provide regular
reports of secondary outcome data distributions. The
CTU will alert RAs to any data that are missing or
inaccurate. The linkage between personal and routine
data and the individual participants will be stored
separately and securely in a password-protected file.
Data security
Wherever possible, all personal and research data will be
entered and stored only in electronic format. Where it is
necessary to store personal or research data in hard
copies, for example where there is no access to a laptop
or where staff complete paper versions of a
questionnaire, data will be stored at the designated NHS
Trust base in a locked filing cabinet. Electronic copies of
personal and study data will be stored on secure shared
drives at each NHS site. All study data will be password-
protected using a password known only to the study
team. No personal or study data will be downloaded or
stored on individual employee drives or desktops. Data
will be entered onto the MACRO eCRF which is the
electronic data management system and is Good Clinical
Practice (GCP) and 21 CFR Part 11 compliant. Research
data will be archived at each site, and centrally for all
centrally collated electronic data and stored for a 10-
year duration in line with sponsor policy. After the 10-
year period, research data will be shredded, deleted or
destroyed using confidential data destruction measures
in place for each organisation. Audio recordings will be
uploaded to the secure shared drive at each site and
stored in an anonymised and encrypted form. The
audio-recording will then be deleted from portable de-
vices within 24 h of recording. Data will be stored confi-
dentially and securely. Anonymised outcome data will be
stored separately from personal information. All data
will be stored in a password-protected format and any
data that is transferred will be done securely and using
encrypted zip files in for example, csv, Stata, SAS or
SPSS format. Data will not be shared with anyone out-
side of the project team and organisations hosting the
research.
Confidentiality {27}
The project team will adhere to Good Clinical Practice
standards, principles and policies for Data Protection,
Security and Confidentiality, consistent with
recommendations from current legislation, including
The Caldicott Report (1997), the British Standard (ISO
IEC 27002) for Information Security, the Data
Protection Act, 1998, the Sussex Partnership NHS
Foundation Trust Research Policy 2012, NHS Research
Governance Framework 2005, HRA and research ethics
approval processes. These principles relate to the need
to protect personal data and guard against any
unauthorised use, inform patients (and professionals) of
its use and allow patients choice regarding how their
personal data is disclosed or used. Participant personal
data will be stored in a secure password-protected file at
each study site. The drive will only be accessible to the
RAs who are employed and working as part of the EIP
clinical and research teams. In both hard and electronic
versions, personal and study data will be kept separate.
Study data will be identified using a participant identifi-
cation number (ID). This ID will be linked to the partici-
pant’s name in a linked file. This file will be password-
protected, with password known only to the study team.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Not applicable. See above 26b there will be no biological
specimens collected.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
A full statistical analysis plan will be written and
independently reviewed prior to unblinding and any
analysis being undertaken.
RCT analysis We will report all participant flow in line
with the CONSORT 2010 Statement extension for cluster
RCTs [80] showing withdrawal and loss to follow-up.
Analyses will be conducted on an intention-to-treat (ITT)
basis. Time to disengagement will be compared between
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trial groups using Cox regression with a gamma-
distributed shared frailty to allow for the clustering by ser-
vice. If this analysis fails to converge, we will employ fully
parametric time-to-event regression analysis with shared
frailty. Analyses will be conducted using Stata v16 or
above (Stata Corporation, College Station, TX, USA).
With a relatively small number of clusters per group, there
is a risk that the type I error rate will be inflated—we will
use a permutation test or similar approach in order to ob-
tain a true significance level. Time to disengagement or
the time beyond which observations are censored (due to
drop-out or end of data collection) will be known for all
participants. Secondary, quantitative outcome measures
will be analysed using mixed regression analysis of all
non-missing data (valid if outcomes are ‘missing at ran-
dom’), with a random effect for service and a Kenward-
Roger small-sample correction. We will investigate the
sensitivity of our conclusions to the missing at random as-
sumption by imputing outcome data under departures
from this assumption. Secondary analyses will be con-
ducted to investigate whether the intervention effect is
mediated by adherence and context effects, as measured
in the process evaluation.
We will adjust for measured service-level factors (e.g.
variation in NICE interventions, deprivation) and
individual-level factors (e.g. ethnicity, gender, duration
of untreated psychosis) which could be important in pre-
dicting outcome: these will be finalised in the statistical
analysis plan prior to locking the database and
unblinding.
Economic analysis The economic analysis will be
composed of
1. A primary cost-effectiveness analysis conducted
from a broad societal perspective including primary
care, social services, police and criminal justice con-
tacts, education and training services and occupa-
tional outcomes. This will examine patient
outcomes (measured using HoNOS scores) along-
side the incremental societal costs arising from the
intervention over the 12-month trial follow-up
period. This will include an assessment of the costs
of investing in staff training in intervention
methods, the cost of increased engagement with
EIP and other NICE-recommended interventions,
cumulative savings from reduced inpatient admis-
sions and A&E contacts and the intervention im-
pact on the cost of wider service contacts and
outcomes (e.g. primary care, police and criminal
justice systems, employment). Data will also be col-
lected on utilisation of education and training ser-
vices, though these activities will not be costed. The
cost-effectiveness analysis will subsequently
combine evidence on the cost implications of the
EYE-2 intervention with health outcomes data
(HoNOS scores) to evaluate whether EYE-2 was
cost-saving (from a societal perspective) and equiva-
lent or superior (to usual care) in terms of patient
outcomes, or whether improved patient outcomes
were achieved at greater overall cost over the
follow-up period of the trial.
2. A secondary analysis of cost-effectiveness that takes
a narrower NHS (commissioner and provider) per-
spective by combining health outcomes data with
an examination of intervention impacts purely
within mental health and other NHS services (e.g.
psychiatric inpatient admissions and A&E attend-
ance). We will also use HoNOS data to determine
the mental health cluster (and therefore tariff) to
which a service user would be allocated based on
assessment of need at 12 months (e.g. a ‘step up’ or
‘step down’ service need). This will serve as a means
to approximate the impact of the intervention on
potential future commissioning resources based on
payments tariffs linked to mental health cluster.
Service use measured through administrative and self-
report data (via the AD-SUS) will be combined and
costed using appropriate unit cost evidence either newly
developed where necessary (if gaps in unit cost evidence
exist) or from existing sources (e.g. Unit costs of Health
and Social care, PSSRU; NHS Reference Costs). Employ-
ment outcomes (including absenteeism or employment
gained or lost) will be valued using the ‘human capital’
approach (using occupational pay rates to value time
spent in or out of paid or unpaid work). Estimated soci-
etal costs per trial participant will be examined in total
and by service sector so that further insight into the dis-
tributional burden of costs by sector for this patient
group can be gained.
The economic evaluation will quantify uncertainty in
cost-effectiveness estimates due to second-order (sam-
pling) uncertainty relating to costs and mental health
outcomes. Where relevant, we will also explore, through
the deterministic one-way sensitivity analysis, the sensi-
tivity of conclusions reached to any key assumptions
required.
Process evaluation analysis The process evaluation will
follow a mixed methods analysis approach. Questionnaire
data will be used to produce scores for implementation
(use of EYE-2 resources with service users) which will be
analysed using mixed regression analysis of all non-
missing data (valid if outcomes are ‘missing at random’),
with a random effect for service and a Kenward-Roger
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small-sample correction to explore changes in scores over
time, for implementation of the EYE-2 intervention
through core mechanisms of coherence, cognitive partici-
pation, collective action and reflexive monitoring. Second-
ary analyses will be conducted to investigate whether the
intervention effect is mediated by adherence and context.
Outcomes across sites will be investigated in relation to
turbulence (macrolevel stressors, complexity and changes
within the NHS) over time. Qualitative interview data will
explore implementation, barriers, facilitators, contextual
effects and turbulence in the service (macro stressors,
complexity, change) over time. Qualitative data will be
analysed using constant comparative analysis [81] and
interpreted in the light of Normalisation Process Theory.
Interim analyses {21b}
Not applicable. There are no interim analyses planned.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
Further details regarding analysis will be provided in the
statistical analysis plan prior to commencing analysis.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Further details regarding analysis will be provided in the
statistical analysis plan.
Plans to give access to the full protocol, participant-level
data and statistical code {31c}
Plans will be made available at a later date.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
Sussex Partnership NHS Foundation Trust will be the
sponsor. At each site, RAs, service user researcher,
service users and carer will form a mini-team, supervised
locally by the site lead, and centrally by the CI and CTU.
Monthly project management meetings chaired by the
CI and involving all co-applicants will manage day-to-
day project management, ensure good communication
between sites, receive monthly site reports on data col-
lection, intervention delivery and progress and address
problems. The trial steering committee (TSC) will com-
prise independent chair, clinical implementation aca-
demic, statistician, health economist and PPI member
plus CTU lead and CI. It will meet 6-monthly, or more
often if required, to provide overall trial supervision and
independent advice, including review of project reports,
protocols, amendments and adherence to protocols.
The CTU will oversee study conduct and ensure
adherence to standard operating procedures (SOPs) and
protocol. The trial manager will work with the study
team to ensure that the study is managed in accordance
with all regulations and governance frameworks. They
will monitor recruitment and study conduct based on a
risk adaptive approach using CTU SOPs and provide
reports to the study team and oversight committees. The
trial manager together with the CI will train staff in
study requirements. Data entry will be quality controlled
by the system as it is being entered (flagging up errors in
real time). The data manager will monitor data
collection and management in accordance with protocol,
including design of data collection tools, undertaking
data validation checks and writing the data management
plan. They will work with sites to ensure all data entry is
accurate and entered in a timely manner. They will
provide data and information for oversight committees
and undertake data cleaning prior to statistical analyses.
All data will be archived in the Trial Master File and
retained securely for a minimum of 5 years following
completion and closure of the trial.
Composition of the data monitoring committee, its role
and reporting structure {21a}
An independent DMEC committee, including clinical
chair, clinical academic and statistician will meet 6-
monthly or more often if required, prior to the TSC. It
will review trial data and serious adverse reactions and
consider if for ethical or safety reasons the trial should
end early. It is independent of the sponsor and there are
no competing interests. The DMEC charter can be
found on the study website at https://www.sussex.ac.uk/
research/projects/eye-2/.
Adverse event reporting and harms {22}
A trial-specific SOP has been written for the monitoring
and reporting of adverse events in this trial. This trial is
unusual in that it is a pragmatic cluster trial which in-
cludes the entire cohort of 20 EIP services in England
for 1 year, followed up for a further year. It is therefore
expected that there will be a very large number of ser-
ious adverse events (SAEs) due to the natural fluctuation
in severity of psychosis experiences in this population,
and the intervention itself is a comparatively low risk so-
cial, motivational and psychoeducation intervention. For
this reason, it was decided to take a pragmatic approach
to reporting of adverse events; this has been discussed
with the trial management team and DMEC, and follows
the approach used in a previous cluster RCT [82]. Clini-
cians and clinical link persons (team leader or clinical
psychologist) in each team will raise to the research
team any SAE that is deemed to be possibly, probably or
definitely related to the trial, for further action. Serious-
ness is defined using standard criteria as (1) resulting in
death; (2) is life threatening (only including self-harm or
suicide ideation or suicide attempt requiring
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hospitalisation or serious threat or act of harm to
others); (3) requires inpatient hospitalisation or pro-
longation of existing hospitalisation (only in the case of
suicide ideation grade 4 or suicide attempt grade 4 or 5
as according to the Common Terminology Criteria for
Adverse Events (CTCAE) version 5.0 November 2017, or
serious threat or act of harm to others requiring hospi-
talisation; (4) resulting in persistent or significant dis-
ability or incapacity. Relatedness criteria include (1)
distress caused by contents of booklet or website; (2) dis-
tress or fatigue caused by answering questionnaires or
taking part in interviews; (3) disappointment at being al-
located to the control group; (4) distress related to the
involvement with or breach of confidentiality related to
involvement of a non-standard member of the social
network such as friend or other non-family member; (5)
distress triggered by attendance at an EYE-2 social
group; (6) distress caused by concern about data security
in the trial (routine data/posts on the forum); (7) distress
caused by a response to a post on the forum or other
forum content; (8) other as deemed by site. Events that
are not serious or not related to the trial (adverse event
(AE), serious adverse event (SAE), unexpected adverse
event (UAE), adverse reaction (AR)) will require no fur-
ther action. Any event rated as at least possibly serious
and possibly related will be reported immediately to the
EIP RA who will gather additional information and
complete a draft serious adverse reaction (SAR) form on
the same day and email this to the CTU and site PI. The
site PI will reassess causality and expectedness and the
CTU will send the information to the CI. Participants
will be followed up until clinical recovery is complete, or
until the event has resolved, and information reported
on the final SAR report. In the absence of the PI, the
form should be completed and signed by another trained
member of the site trial team who is named on the dele-
gation log (as designated by local PI). The PI should sub-
sequently check the SAR form, make changes as
appropriate, sign and then send to the Brighton and Sus-
sex CTU as soon as possible. The patient must be identi-
fied by trial number. The patient’s name should not be
used on any correspondence. This final SAR report is
then graded SAR or suspected unexpected serious ad-
verse reaction (SUSAR) on the basis of expectedness
judged by the PI and CI. The CTU will notify the re-
search ethics committee of SUSARs as per the condi-
tions of the favourable opinion and according to
CTUSOP018 within 15 calendar days of the CTU first
being notified of the event. The CI and independent
clinical reviewer will assess any possible SARs. Events re-
corded as serious, related and expected (SAR) will be
submitted to the DMEC and sponsor as required. Any
events rated as also unexpected (SUSAR) will also be re-
ported to the REC within 15 days of first notice. This
may involve the DMEC members being unblinded to the
trial group or seeking further data. If there are any eth-
ical or safety reasons why the trial should be prema-
turely ended, they will advise the TSC accordingly.
Frequency and plans for auditing trial conduct {23}
Auditing of trial conduct will be conducted regularly by
the CTU, including monitoring of site file completion
and conduct at each site, 6-monthly by the TSC and
DMEC, and annually by the sponsor.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
All protocol amendments will be submitted for HRA/
ethics approval, and revised protocols provided to the
funder. All approved amendments will be communicated
by the CTU to all site PIs and local governance teams
prior to implementation.
Dissemination plans {31a}
The study website (www.sussex.ac.uk/research/projects/
eye-2) will be a focal point for disseminating outputs,
through newsletters, presentations, high-impact peer-
reviewed academic and service user publications and a
tailored VLOG to service users, relatives, teams, regional
and national networks. Participants will be able to pro-
vide comments and suggestions for dissemination. All
national services will be invited to a results launch event,
which will be recorded and added to the study website,
along with other outputs. The implementation toolkit
will be formed into a series of implementation packages,
tailored to different contexts, including training, man-
uals, checklists, website, booklets, schools pack and so-
cial involvement protocols. These will be made available
to clinicians, managers and services to support delivery
in the NHS. A broader package of learning, relating to
implementation in youth and mental health services, will
be made available for other youth and psychosis services
(NHS and non-statutory). The commissioning guide, de-
veloped with our GP commissioner, will be provided for
commissioning purposes. Our collaboration with NHS
England EIP lead (JN) will allow us to adapt approaches
and materials during the study, and release these to sup-
port and guide future NHS England targets. We will
present our findings to the public, participants, services
and academic audiences through the Sussex Psychosis
Research Interest Group, and other site-specific and
local feedback events, national and international confer-
ences. We will draw on our national collaborations, and
regional links, so that if effective, we can readily dissem-
inate the outcomes of this study, and guidance for im-
plementation to all EIP teams in England, alongside the
manuals, and commissioner guidance. A series of Tweet
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chats involving national and international colleagues, of-
fered to services throughout the UK, will support further
implementation planning. Researchers, clinicians and
services will thus be kept informed and able to use new
information regarding (i) the effectiveness and cost-
effectiveness of the intervention; (ii) the engagement
needs of ethnic minority EIP populations and (iii) varia-
tions in implementation and outcomes based on NHS
service context, turbulence, macro and micro stressors.
Service users and families will thus, in a timely manner,
receive engagement-focussed services, supported by
‘myth-busting’ resources that address their personal
goals and needs.
EIP services throughout the UK will be supported to
implement the EYE intervention. The results of the
study, if effective and cost-effective, will be widely dis-
seminated through our network of regional and national
channels, to clinicians, services, trusts and CCGs, sup-
ported by NHS England. We will offer a set of training
and implementation packages tailored to different con-
texts and services, including manuals, resources and
commissioner guides. The Normalisation Process The-
ory framework will enable us to lay out specific changes
that will be required in terms of roles and responsibil-
ities, beliefs, behaviours, relationships, processes and
structures to deliver the EYE-2 approach at an individ-
ual, social network, service and NHS trust level. This will
enable a real and meaningful change in how individuals
work and services are delivered, based on core EYE
intervention principles.
Discussion
Over the past 20 years, significant gains have been made
nationally and internationally in ensuring that early
detection and intervention services are available for
young people who develop psychosis for the first time,
and their families. Substantial recent investment has
helped to reduce waiting times to 2 weeks from referral
to allocation to a care coordinator, for the majority of
cases, as well as ensuring that EIP service provision is
equipped with a full range of NICE-recommended treat-
ment options. Yet approximately 25% of young people
disengage prematurely without receiving the full benefit
of these services and at significant potential cost to their
mental health. Whilst strategies are in place to support
engagement with an assessment process, there are no in-
terventions aimed at improving engagement in the lon-
ger term, and as young people begin to disengage.
The EYE-2 trial is the first to evaluate a specific
engagement-focussed intervention for young people with
psychosis. The pragmatic cluster RCT design will evalu-
ate effectiveness and cost-effectiveness. The use of NHS
England mandated outcomes serves to strengthen
follow-up data completion, across the whole sample, in-
cluding for those who are disengaging. The implementa-
tion process evaluation, delivery through routine clinical
service structures and provision of an implementation
tool kit, training programme and resources will ensure
that the intervention is highly scalable and will distin-
guish it from standard EIP care. Staff responses to the
process evaluation and booster training will ensure that
the intervention can be adapted to suit a variety of ser-
vice structures, clinician needs and preferences, both
within and beyond EIP.
Patient and public involvement (PPI) has been integral
to the conduct, intervention and resource development
in the original EYE project and PPI continues to be
integral to the current study design. PPI will be led from
the McPin Foundation (specialists in mental health
service user research). PPI activities will include (i)
contribution to steering group and study meetings; (ii)
reviewing ethics, recruitment and advertising materials;
(iii) supporting training delivery at each site; (iv)
supporting the delivery of the social groups at each
intervention site; (v) co-facilitating the lived experience
group at each site; (vi) contributing to the dissemination
plan. In each site, the senior PPI lead, 2 service users
and a parent will be involved in the local EYE-2 staff
training and EYE-2 social group programme. The entire
PPI team will contribute to articles, VLOGS and study
newsletters. All of this previous and planned work will
ensure that the intervention and materials remain highly
valued by clinicians, service users and their families and
that service users continue to feel they have more
choices, enhanced goals, increased hope, trust and qual-
ity of life.
Trial status
The protocol is version 4: Dated 3rd April 2020. Service
user identification (recruitment) began on 13th May
2019 and is expected to complete during July 2020.
Supplementary Information
The online version contains supplementary material available at https://doi.
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